Clinical Trial Update: Neoadjuvant Nab-Paclitaxel and S-1 in Borderline Resectable Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update investigating neoadjuvant nab-paclitaxel and S-1 in borderline resectable pancreatic cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Borderline Resectable Pancreatic Cancer

Drugs mentioned

• Nab-paclitaxel (paclitaxel protein-bound)
• S-1 (tegafur/gimeracil/oteracil)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Borderline Resectable Pancreatic Cancer | Phase 2 | Status: UNKNOWN